Neoantigen, a peptide fragment formed by genetic mutation, gives immunologist a new target for cancer therapy.
Introduction 2 1
Breast cancer is the most common tumor in female and there are more than 500,000 women worldwide died of peptide as the negative control. Subsequently, cells were stained by anti-human HLA-A2 antibody (BB7.2, 1 0 3
BioLegend, USA) with PE-labeled. FI (Fluorescence index) value was used as the evaluation standard. Refer to 1 0 4 previous assessment criteria, FI = (mean FITC fluorescence for the given peptide-mean FITC fluorescence 1 0 5 without peptide) / (mean FITC fluorescence without peptide) (Lv et al., 2009 ). To induce neoantigens specific CTLs, we first isolated the peripheral blood mononuclear cells (PBMCs) from 1 0 9 healthy donors by Ficoll-Paque PLUS density gradient centrifugation (GE Healthcare, USA), CD8 + T cells were 1 1 0 sorted from PBMC by CD8 MicroBeads (human) (Miltenyi, Germany) and were cryopreserved until use. Then the 1 1 1 PBMC without CD8 + T cells were used to generate monocyte-derived dendritic cells (DCs) by plastic adherence 1 1 2 culture method. DC precursor cells were seeded into plates in AIM-V medium (Gibco, USA) supplemented with 1 1 3 5% autologous serum, 80ng/ml GM-CSF (Gibco, USA), 100ng/ml IL-4 (Gibco, USA) for 48h, and then added half 1 1 4 amount of medium contain 1ug/ml CD40L(Peprotech, USA)and 250u/ml IFN-γ(Peprotech, USA)to induce 1 1 5 monocyte differentiated into DCs and matured for 48h. DCs were pulsed with 10ug/ml candidate peptides 1 1 6 overnight and recovered cryopreserved CD8 + T cells rest for overnight. Following the day, DCs were collected and 1 1 7 cocultured with autologous CD8 + T cells with the ratio between 1:4 to 1:10 in AIM-V medium with 5% autologous 1 1 8 serum and 30 ng/ml IL-21 (Cellgenix, Germany). Two days later, human recombinant IL-2 (2 ng/ml) (Gibco, USA), 1 1 9 IL-7 (10 ng/ml) (Peprotech, USA) and IL-15 (1 ng/ml) (Peprotech, USA) were supplemented and repeat every two 1 2 0 days. After two rounds of stimulation, neoantigens specific CTLs were harvested to carry out Cytotoxic assay and 1 2 1 ELISPOT. Enzyme-linked immunospot assay relies on quantifying IFN-γ-releasing to identify specific T cells. This method is 1 2 5 similar to before (Depla et al., 2008) and were performed using a Human IFN-gamma ELISpot PLUS kit (Mabtech, 1 2 6 Sweden) according to the manufacturer's instruction. Briefly,10ug/ml candidate peptides, 10ug/ml positive control 1 2 7 peptides and 10ug/ml negative peptides were loaded on T2 or HCT116 cells respectively for 4h and co-incubate with specific CTLs at the ratio 1:4 (2500 T2 or HCT116 cells:10000 CTLs) in 96-well plate for 20h at 37°C, in cell that response to peptide-pulsed T2 or HCT116 cells. The standard we set are similar to previously: (number 1 3 3 of experimental peptide spots)/(number of unrelated peptide spots)> 2 (Yamamiya et al., 2018) . Cytotoxicity assay was performed with a CytoTox 96® Non-Radioactive Cytotoxicity Assay kit (Promega, USA) 1 3 7 according to manufacturer's instruction. We attempted to test the cytotoxicity of CTLs to target cells (T2 cells) 1 3 8 loaded with 10ug/ml candidate peptides, negative peptides (APOL1 176-184 : ALADGVQKV) and without peptides. In our experiment, peptide-specific CTLs were co-cultured with T2 cells loaded with candidate peptides/negative 1 4 0 peptides in different effector: target ratios (10:1 and 1:1) and incubated for 4h in 96-well V-bottom plate. We set control group according to instruction: effector cell spontaneous release group, target cell spontaneous release 1 4 2 group, maximum release group, culture medium background control, volume correction control. After adding lysis used to terminate the reaction. Finally, we measured the absorbance at 490nm and recorded the value. Our objective was to discern neoantigens derive from missense mutation base on neoantigen prediction system, breast cancer in the future. We established a candidate epitopes prediction system similar to the method 1 5 5 previously described (Johanns et al., 2016) . We identified 39,401 missense mutations from 969 patient's tumor 1 5 6 genomic data from TCGA, ICGC and an article. We determined 9,913 candidate epitopes (HLA-A*0201, length=9 1 5 7 mer) through the combination of six affinity prediction algorithms and the filter of IC50 < 500 nM in at least two 1 5 8 algorithms (Fig.1a ). The top 30 candidate epitopes were listed for further assessment at final base on mutation 1 5 9 frequency and the mean of six binding score (Table 1) . We found PIK3CA mutated in 8 of 40 breast cancers 1 6 0 through our prediction system. As the previous description, high frequency of mutations of oncogenic PIK3CA To further confirm the binding affinity of candidate peptides, peptides were synthesized and T2 cells peptide binding assay was test. T2 is a cell line deficient in transporter associated with antigen processing (TAP), causing were used to detect the ability of candidate peptides binding to HLA. The higher the binding ability, the higher the 1 7 0 expression level of MHC molecules on the cell surface (Hansen & Myers, 2003) . We screened 10 high-affinity To identify the immunogenicity of these 10 neoantigens with high affinity, CD8 + T cells were separated from 1 7 6 HLA-A*0201 healthy human donators and were stimulated in vitro by DCs loaded with these ten candidate 1 7 7 peptides. The experiment process is shown in Fig.1b . After two rounds of stimulation, neoantigen specific T cells 1 7 8 were amplified and used to perform IFN-γ ELISPOT assay and Cytotoxicity assay. Seven of ten (70%) candidate 1 7 9 peptides induced specific CTLs response when compare the number of IFN-γ between candidate peptides and 1 8 0 unrelated peptides (APOL1) (Figs. 2 a and b) . Two peptides were derived from the PIK3CA among these 7 Furthermore, we tested the cytotoxicity of neoantigen specific T cells via Cytotoxicity assay. T2 cells loaded with 1 8 6 neoantigens as the target cells were applied in cytotoxicity assays. There are 5 peptides (50%) can induce 1 8 7 specific CTLs respond to the peptide specific pulsed T2, including TWISTNB , PIK3CA, COL14A1, SLC13A3 1 8 8 and CDC37L1 (Fig.3) . As we expected, these specific CTLs could lyse the T2 cells pulsed with candidate 1 8 9 peptides more efficiently than Irrelevant peptides, and these five peptides were concluded in those 7 specific 1 9 0 peptides tested in ELISPOT. This result confirmed that these predicted neoantigens can cause specific T cell 1 9 1 immune response and destroy target cells specifically in vitro. Similar to the results of ELISPOT, we observed the 1 9 2 peptide KLMGIVYKV derive from TWISTNB has the strongest ability to induce T cells respond and lyse target 1 9 3 cells (the percentage of specific lyse increase about 35% from 1:1 to 10:1) in those 5 immunogenic peptides. To further describe the specificity of neoantigen from TWISTNB and confirm the cross-immune response in wild 1 9 7 type (WT)-peptide and mutant type (MT)-peptide, we generated the MT-peptide/WT-peptide specific CTLs 1 9 8 respectively in vitro and carried out ELISPOT assay. As the result, MT-peptide specific CTLs can recognized T2 1 9 9 cells loaded with MT-peptide and secret IFN-γ but not responded to the wild-type peptide pulsed T2 (p<0.01) 2 0 0 ( Fig.4a) . Similarly, the WT-peptide specific CTLs can only respond to WT-peptide pulsed T2 in ELISPOT assay 2 0 1 (Fig.4b) . Above results indicated that the TWISTNB-derived neoantigen can be recognized by specific-CTLs and 2 0 2 there is no cross-immune response with wild-type. We next used TWISTNB-induced CTLs to target genetically 2 0 3 modified HCT116 cells and wild-type HCT116 cells in ELISPOT assay. Results shown that compared with 2 0 4 wild-type HCT116 cells, specific CTLs secreted IFN-γ significantly increase (p<0.01) (Fig.4c) , indicated that the 2 0 5 neoantigen derive from TWISTNB can present on the surface of tumor cell line and identified by specific-CTLs. In further verification, we found that neoantigen from TWISTNB can induce immune responses in 7 random different 2 0 7 donators in vitro(P<0.05) (Fig.5 ). We suppose that this neoantigen may serve as a positive control for the 2 0 8 prediction of neoantigen in breast cancer and as the target for immunotherapy, such as DC-CTLs, neoantigen 2 0 9 cancer vaccine and TCR-T (T cell receptor). In our study, we obtained 285,283 SNVs contain 39,401 missense mutations from breast cancer samples analyzed the immunogenicity of candidate neoantigens in vitro. We conducted cell experiments in vitro using T 2 1 5 cells of healthy donors for filtering precise candidate neoantigens, 7/10 neoantigens were immunogenic 2 1 6 consistent with ELISPOT assay criteria, 5/10 were capable of inducing specific T cells to cleave target cells 2 1 7 loaded with neoantigens, these five immunogenic peptides were contained in those 7 neoantigens verified by ELISPOT. For mutation-type peptide derive from TWISTNB, ELISPOT and Cytotoxicity assay revealed stronger specific immune responses compare with other neoantigens, without cross-reactivity against the wild-type. In
We did not choose the patient's peripheral blood or tumor cells to screen neoantigens, but the peripheral blood 2 3 8 of healthy donors. Strønen et al., in 2016 , demonstrated that using T lymphocytes from healthy donors to validate 2 3 9 tumor-specific neoantigens, establishing T cells repositories that can specifically identify tumor neoantigens, and 2 4 0 providing more possibilities for discovering new targets for tumors immunotherapy (Strønen et al., 2016) . Other 2 4 1 researchers also used T cells from healthy donors in the study of tumor-specific T cell receptors for avoiding such 2 4 2 an event that the existing T cells are prevented from being activated again or initiating specific T cells in 2 4 3 patients . It can be seen that it is effective to use healthy donor T cells to optimize neoantigens. In our study, we identified a neoantigen derive from TWISTNB in breast cancer using healthy donator T cells and the neoantigen maybe applied in TCR-T, DC vaccine, peptide vaccine and DC-CTLs and others anti-tumor magazines were used for bioinformatics analysis and cell experiments. And we discovered a neoantigen derive 2 7 2 from TWISTNB, which can induce immune response in 7 random individuals. With this neoantigen, we will devote we can strive to achieve an objective that find shared biomarker that can target recurrent, metastatic and 2 7 5 refractory breast cancer. It is beneficial to explore a high-frequency neoantigen target that can be shared in 2 7 6 multiple cancers, identify abundant high-frequency neoantigens and create neoantigen library for immunotherapy. This study was supported financially with funds from Science, Technology and Innovation Commission of 
